MY156431A - Methods of treating proliferative skin diseases using carbazole derivatives - Google Patents

Methods of treating proliferative skin diseases using carbazole derivatives

Info

Publication number
MY156431A
MY156431A MYPI20054257A MYPI20054257A MY156431A MY 156431 A MY156431 A MY 156431A MY PI20054257 A MYPI20054257 A MY PI20054257A MY PI20054257 A MYPI20054257 A MY PI20054257A MY 156431 A MY156431 A MY 156431A
Authority
MY
Malaysia
Prior art keywords
methods
proliferative skin
skin diseases
carbazole derivatives
treating proliferative
Prior art date
Application number
MYPI20054257A
Other languages
English (en)
Inventor
Samuel R Denmeade
Robert L Hudkins
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MY156431A publication Critical patent/MY156431A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MYPI20054257A 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives MY156431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60920304P 2004-09-10 2004-09-10
US11/222,409 US20060058250A1 (en) 2004-09-10 2005-09-08 Methods of treating proliferative skin diseases using carbazole derivatives

Publications (1)

Publication Number Publication Date
MY156431A true MY156431A (en) 2016-02-26

Family

ID=36034857

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20054257A MY156431A (en) 2004-09-10 2005-09-09 Methods of treating proliferative skin diseases using carbazole derivatives

Country Status (14)

Country Link
US (1) US20060058250A1 (https=)
EP (1) EP1786418A1 (https=)
JP (1) JP2008512497A (https=)
KR (1) KR20070113186A (https=)
AR (1) AR050930A1 (https=)
AU (1) AU2005285007A1 (https=)
BR (1) BRPI0515115A (https=)
CA (1) CA2577024A1 (https=)
IL (1) IL181003A0 (https=)
MX (1) MX2007002532A (https=)
MY (1) MY156431A (https=)
NO (1) NO20071052L (https=)
TW (1) TW200621266A (https=)
WO (1) WO2006031772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
DK1044203T3 (da) * 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1309721A2 (en) * 2000-08-11 2003-05-14 Cephalon, Inc. Modulating multiple lineage kinase proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
JP2008512497A (ja) 2008-04-24
BRPI0515115A (pt) 2008-07-01
MX2007002532A (es) 2007-05-09
EP1786418A1 (en) 2007-05-23
AR050930A1 (es) 2006-12-06
IL181003A0 (en) 2007-07-04
TW200621266A (en) 2006-07-01
AU2005285007A1 (en) 2006-03-23
KR20070113186A (ko) 2007-11-28
WO2006031772A1 (en) 2006-03-23
US20060058250A1 (en) 2006-03-16
NO20071052L (no) 2007-04-03
CA2577024A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MX2009004060A (es) Moduladores de proteina cinasa de triazolpiridazina.
SI2324008T1 (sl) 3,4-diarilpirazoli kot protein-kinazni inhibitorji
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA201101507A1 (ru) Способы лечения солидных опухолей
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MX2010004074A (es) Combinacion 059.
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
IL189546A0 (en) Therapy for the treatment of disease
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
MX2012001708A (es) Anticuerpo humanizado anti-oligomero de amiloide b.
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
TW200612922A (en) Inhibitors of hsp90
IN2012DN02816A (https=)
WO2010025135A3 (en) Trimeprazine and ethopropazine derivatives for promoting bone growth
MY156431A (en) Methods of treating proliferative skin diseases using carbazole derivatives
WO2007115092A3 (en) 10-substituted cytisine derivatives and methods of use thereof